Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In March
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In March
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
医疗保健领域超卖次数最多的股票为买入被低估的公司提供了机会。
The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.
RSI 是一种动量指标，它比较股票在价格上涨的日子和价格下跌的日子的走势。与股票的价格走势相比，它可以让交易者更好地了解股票在短期内的表现。根据Benzinga Pro的数据，当相对强弱指数低于30时，资产通常被视为超卖。
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
以下是该行业主要超卖参与者的最新名单，RSI接近或低于30。
Pacific Biosciences of California, Inc. (NASDAQ:PACB)
加州太平洋生物科学有限公司（纳斯达克股票代码：PACB）
- On Feb. 15, Pacific Biosciences posted a narrower-than-expected quarterly loss. "Our team successfully executed its goals in 2023 and launched PacBio on a trajectory this company has never seen before," said Christian Henry, President and CEO of PacBio. "We continue to build solutions across the workflow, allowing our customers to further scale on HiFi, and we are encouraged to see how researchers are already making discoveries and shifting paradigms with the power and economics of Revio and the extraordinary accuracy of Onso." The company's stock fell around 27% over the past five days and has a 52-week low of $4.0050 .
- RSI Value: 28.98
- PACB Price Action: Shares of Pacific Biosciences of California fell 4% to close at $4.1750 on Wednesday.
- 2月15日，太平洋生物科学公布的季度亏损低于预期。PacBio总裁兼首席执行官克里斯蒂安·亨利表示：“我们的团队在2023年成功实现了目标，并以该公司从未见过的轨迹启动了PacBio。”“我们将继续在整个工作流程中构建解决方案，使我们的客户能够在HiFi上进一步扩大规模，看到研究人员如何利用Revio的力量和经济性以及Onso的非凡精度做出发现并改变范式，我们感到鼓舞。”该公司的股票在过去五天中下跌了约27％，并且 52 周低点为 4.0050 美元 。
- RSI 值：28.98
- PACB价格走势：加州太平洋生物科学公司股价周三下跌4％，收于4.1750美元。
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)
艾恩伍德制药公司（纳斯达克股票代码：IRWD）
- On Feb. 29, Ironwood Pharmaceuticals released topline results from its pivotal Phase 3 STARS trial of once-weekly subcutaneous apraglutide in reducing parenteral support (PS) (drugs given by routes other than the digestive tract) dependency in adult patients with short bowel syndrome with intestinal failure (SBS-IF). The company's stock fell around 19% over the past five days. It has a 52-week low of $8.07.
- RSI Value: 21.99
- IRWD Price Action: Shares of Ironwood Pharmaceuticals fell 7.5% to close at $8.62 on Wednesday.
- 2月29日，Ironwood Pharmicals发布了其关键的三期STARS试验的主要结果，该试验每周一次的皮下阿普拉鲁肽可减少成年短肠综合征合并肠衰竭（SBS-IF）患者的肠外支持（PS）（通过消化道以外途径给药的药物）依赖。该公司的股票在过去五天中下跌了约19％。它 创下 52 周低点 8.07 美元。
- RSI 值：21.99
- IRWD价格走势：周三，艾恩伍德制药股价下跌7.5％，收于8.62美元。
Integra LifeSciences Holdings Corporation (NASDAQ:IART)
Integra 生命科学控股公司（纳斯达克股票代码：IART）
- On Feb. 28, Integra Lifesciences posted downbeat quarterly results. The company's stock fell around 8% over the past five days and has a 52-week low of $33.44.
- RSI Value: 28.88
- IART Price Action: Shares of Integra LifeSciences fell 1.2% to close at $36.11 on Wednesday.
- 2月28日，Integra Lifesciences公布了悲观的季度业绩。该公司的股票在过去五天中下跌了约8％，为期52周 最低价为33.44美元。
- RSI 值：28.88
- IART价格走势：周三，Integra LifeSciences的股价下跌1.2％，收于36.11美元。
Read More: Kroger, Broadcom And 3 Stocks To Watch Heading Into Thursday
阅读更多： 克罗格、博通和三只股票在周四值得关注